Pharming Group (OTCMKTS:PHGUF) Posts Earnings Results

Pharming Group (OTCMKTS:PHGUF) announced its earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, reports. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The company had revenue of $106.50 million for the quarter, compared to analyst estimates of $89.72 million.

Pharming Group Stock Performance

Shares of Pharming Group stock remained flat at $1.51 on Friday. Pharming Group has a 12 month low of $0.79 and a 12 month high of $2.17. The company’s fifty day moving average is $1.77 and its two-hundred day moving average is $1.61. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.16 and a quick ratio of 2.39.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.